At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SHPH Shuttle Pharmaceuticals Inc
Market Closed 02-14 16:00:00 EST
0.6997
+0.0087
+1.26%
盘后0.7066
+0.0069+0.99%
17:45 EST
High0.7080Low0.6800Vol77.41K
Open0.6800D1 Closing0.6910Amplitude4.05%
Mkt Cap2.85MTradable Cap2.26MTotal Shares4.08M
T/O53.59KT/O Rate2.39%Tradable Shares3.23M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine
TIPRANKS  ·  01-21
Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
THOMSON REUTERS  ·  01-21
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GlobeNewswire  ·  01-21
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF
TIPRANKS  ·  2024-12-19
Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF
Shuttle Pharma Enters Into Sponsored Research Agreement With the University of California, San Francisco to Advance Psma Development Program
THOMSON REUTERS  ·  2024-12-19
Shuttle Pharma Enters Into Sponsored Research Agreement With the University of California, San Francisco to Advance Psma Development Program
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
GlobeNewswire  ·  2024-12-19
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
Shuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line
TIPRANKS  ·  2024-11-26
Shuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line
BRIEF-Shuttle Pharma Expands Patient Enrollment For Phase 2 Clinical Trial
Reuters  ·  2024-11-26
BRIEF-Shuttle Pharma Expands Patient Enrollment For Phase 2 Clinical Trial
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma as Uva Cancer Center Doses Its First Patient
THOMSON REUTERS  ·  2024-11-26
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma as Uva Cancer Center Doses Its First Patient
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
GlobeNewswire  ·  2024-11-26
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
Shuttle Pharmaceuticals Q3 EPS $(1.59) Down From $(0.91) YoY
Benzinga  ·  2024-11-14
Shuttle Pharmaceuticals Q3 EPS $(1.59) Down From $(0.91) YoY
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
THOMSON REUTERS  ·  2024-11-14
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
GlobeNewswire  ·  2024-11-14
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
Shuttle Pharmaceuticals Prices $4.5 Million Public Offering
MT Newswires Live  ·  2024-10-30
Shuttle Pharmaceuticals Prices $4.5 Million Public Offering
Shuttle Pharmaceuticals dips 6%, prices $4.5M share offering
seekingalpha  ·  2024-10-30
Shuttle Pharmaceuticals dips 6%, prices $4.5M share offering
BRIEF-Shuttle Pharmaceuticals Holdings Announces Pricing Of $4.5 Mln Public Offering
Reuters  ·  2024-10-30
BRIEF-Shuttle Pharmaceuticals Holdings Announces Pricing Of $4.5 Mln Public Offering
Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share
TIPRANKS  ·  2024-10-30
Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  2024-10-30
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced at-the-Market Under Nasdaq Rules
Shuttle Pharmaceuticals Holdings Inc - Prices Public Offering of up to 2.9 Mln Shares of Common Stock and Warrants at$1.525 per Share
THOMSON REUTERS  ·  2024-10-30
Shuttle Pharmaceuticals Holdings Inc - Prices Public Offering of up to 2.9 Mln Shares of Common Stock and Warrants at$1.525 per Share
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire  ·  2024-10-30
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Introduction

Company Name.
Shuttle Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Issue price:
--